$NEPH
NEPHROS INC Stock $neph

$neph Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415064180 Filed on November 10, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$510.0K	$320.0K	$521.0K
YoY Change	50.0%	-34.83%	18.14%
Cost Of Revenue	$260.0K	$154.0K	$209.0K
YoY Change	100.0%	-12.0%	47.18%
Gross Profit	$250.0K	$166.0K	$312.0K
YoY Change	13.64%	-47.47%	4.35%
Gross Profit Margin	49.02%	51.88%	59.88%
Selling, General & Admin	$890.0K	$974.0K	$740.0K
YoY Change	28.99%	27.32%	5.71%
% of Gross Profit	356.0%	586.75%	237.18%
Research & Development	$240.0K	$226.0K	$160.0K
YoY Change	-7.69%	26.97%	-11.11%
% of Gross Profit	96.0%	136.14%	51.28%
Depreciation & Amortization	$0.00	$50.00K	$60.00K
YoY Change			-50.0%
% of Gross Profit	0.0%	30.12%	19.23%
Operating Expenses	$1.190M	$1.253M	$952.0K
YoY Change	19.0%	25.68%	1.82%
Operating Profit	-$940.0K	-$1.087M	-$594.0K
YoY Change	20.51%	59.62%	-6.6%
Interest Expense	-$10.00K	$9.000K	$9.000K
YoY Change	-99.78%	-86.15%	-47.06%
% of Operating Profit
Other Income/Expense, Net	$10.00K	-$11.00K	-$16.00K
YoY Change	-50.0%	-126.83%	1500.0%
Pretax Income	-$940.0K	-$580.0K	-$1.820M
YoY Change	-82.1%	-121.32%	-65.92%
Income Tax
% Of Pretax Income
Net Earnings	-$940.0K	-$581.0K	-$1.815M
YoY Change	-82.1%	-121.34%	-66.0%
Net Earnings / Revenue	-184.31%	-181.56%	-348.37%
Basic Earnings Per Share		-$0.02	-$0.06
Diluted Earnings Per Share	-$188.0K	-$0.02	-$524.5K
COMMON SHARES
Basic Shares Outstanding	45.03M shares	32.62M shares	31.19M shares
Diluted Shares Outstanding		32.62M shares	31.19M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.250M	$1.810M	$1.040M
YoY Change	-2.34%	72.38%	352.17%
Cash & Equivalents	$1.250M
Short-Term Investments
Other Short-Term Assets	$230.0K	$90.00K	$60.00K
YoY Change	121.15%	200.0%	1.69%
Inventory	$590.0K	$665.0K	$419.0K
Prepaid Expenses
Receivables	$400.0K	$216.0K	$295.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.460M	$2.779M	$1.812M
YoY Change	46.08%	103.29%	223.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.00K	$0.00	$0.00
YoY Change	900.0%	-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.490M	$1.526M	$1.579M
YoY Change	-11.52%	-12.15%	-11.74%
Total Long-Term Assets	$1.510M	$1.526M	$1.579M
YoY Change	-10.39%	-12.2%	-11.89%
TOTAL ASSETS
Total Short-Term Assets	$2.460M	$2.779M	$1.812M
Total Long-Term Assets	$1.510M	$1.526M	$1.579M
Total Assets	$3.970M	$4.305M	$3.391M
YoY Change	17.84%	38.65%	44.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$650.0K	$924.0K	$990.0K
YoY Change	-22.16%	1.54%	-3.88%
Accrued Expenses	$240.0K	$154.0K	$306.0K
YoY Change	-29.82%	-48.67%	31.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$960.0K	$1.148M	$1.364M
YoY Change	-23.02%	-62.45%	-19.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$350.0K	$370.0K	$7.960M
YoY Change	-95.51%	-13.95%	1668.89%
Total Long-Term Liabilities	$350.0K	$370.0K	$7.960M
YoY Change	-95.51%	-13.95%	1668.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$960.0K	$1.148M	$1.364M
Total Long-Term Liabilities	$350.0K	$370.0K	$7.960M
Total Liabilities	$1.310M	$1.513M	$9.320M
YoY Change	-85.52%	-56.65%	336.33%
SHAREHOLDERS EQUITY
Retained Earnings		-$116.3M	-$115.7M
YoY Change		3.01%	0.08%
Common Stock		$45.00K	$32.00K
YoY Change			28.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.660M	$2.792M	-$5.929M
YoY Change
Total Liabilities & Shareholders Equity	$3.970M	$4.305M	$3.391M
YoY Change	17.84%	38.42%	44.18%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	-$940.0K	-$581.0K	-$1.815M
YoY Change	-82.1%	-121.34%	-66.0%
Depreciation, Depletion And Amortization	$0.00	$50.00K	$60.00K
YoY Change			-50.0%
Cash From Operating Activities	-$1.240M	-$1.130M	-$530.0K
YoY Change	47.62%	43.04%	112.0%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.230M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	690.0K	1.890M	1.210M
YoY Change	-35.51%	17.39%
NET CHANGE
Cash From Operating Activities	-1.240M	-1.130M	-530.0K
Cash From Investing Activities	-10.00K
Cash From Financing Activities	690.0K	1.890M	1.210M
Net Change In Cash	-560.0K	760.0K	680.0K
YoY Change	-343.48%	-7.32%	-372.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.240M	-$1.130M	-$530.0K
Capital Expenditures	-$10.00K
Free Cash Flow	-$1.230M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In One Year ExpectedRecognitionOfUnrecognizedCompensationCostsDueInOneYear	0.32	pure
	us-gaap	Net Income Loss NetIncomeLoss	-6127000	USD
	us-gaap	Depreciation Depreciation	1000	USD
	us-gaap	Depreciation Depreciation	6000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	158000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	158000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	216000	USD
CY2015Q3	us-gaap	Cash Cash	1813000	USD
CY2014Q4	us-gaap	Cash Cash	1284000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	665000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	186000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	85000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	2779000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	1684000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1526000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1684000	USD
CY2015Q3	us-gaap	Assets Assets	4305000	USD
CY2014Q4	us-gaap	Assets Assets	3369000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	924000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	835000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	154000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	342000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	70000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	70000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1148000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1247000	USD
CY2015Q3	neph	Warrant Liability WarrantLiability	0	USD
CY2014Q4	neph	Warrant Liability WarrantLiability	7386000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	216000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	365000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	417000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	1513000	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	4007000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2153000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	8811000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	216000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1205000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	298000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1323000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	765000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	46000	USD
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	193000	USD
	us-gaap	Licenses Revenue LicensesRevenue	110000	USD
	us-gaap	Licenses Revenue LicensesRevenue	641000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	320000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	30000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	118993000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	108382000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	72000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	72000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116318000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114165000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	2792000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-5681000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4305000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3369000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	274000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	491000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1433000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1406000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	154000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	175000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	626000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	423000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	166000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	316000	USD
	us-gaap	Gross Profit GrossProfit	807000	USD
	us-gaap	Gross Profit GrossProfit	983000	USD
CY2015Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	226000	USD
CY2014Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	178000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	582000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	521000	USD
CY2015Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	53000	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	159000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	164000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	974000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	765000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2551000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2177000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	1253000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	997000	USD
	us-gaap	Operating Expenses OperatingExpenses	3292000	USD
	us-gaap	Operating Expenses OperatingExpenses	2862000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1087000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-681000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2485000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1879000	USD
CY2015Q3	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-2287000	USD
CY2014Q3	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-3428000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-52000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-23000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2575000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1664000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1340000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2013000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1762000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1500000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3102000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2134000	USD
	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	2000	USD
	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	-2000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	321000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	173000	USD
	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	0	USD
	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	31000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-3000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	40000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	119000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	57000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	479000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-24000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-56000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-92000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	529000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	468000	USD
CY2013Q4	us-gaap	Cash Cash	579000	USD
CY2014Q3	us-gaap	Cash Cash	1047000	USD
	us-gaap	Interest Paid InterestPaid	34000	USD
	us-gaap	Interest Paid InterestPaid	70000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1230000	USD
CY2015Q2	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	0.67
	neph	Fair Value Of Calculated Aggregate Value FairValueOfCalculatedAggregateValue	5287	USD
CY2014	neph	Fair Value Of Calculated Aggregate Value FairValueOfCalculatedAggregateValue	7386	USD
	neph	Weighted Average Exercise Price Fair Value WeightedAverageExercisePriceFairValue	0.30
CY2014	neph	Weighted Average Exercise Price Fair Value WeightedAverageExercisePriceFairValue	0.3
	neph	Closing Price Per Share Of Common Stock Fair Value ClosingPricePerShareOfCommonStockFairValue	0.40
CY2014	neph	Closing Price Per Share Of Common Stock Fair Value ClosingPricePerShareOfCommonStockFairValue	0.79
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.37	pure
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.369	pure
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P4Y2M12D
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.014	pure
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.016	pure
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	205000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	318000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y8M12D
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Current Year ExpectedRecognitionOfUnrecognizedCompensationCostsDueInCurrentYear	0.09	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Two Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInTwoYears	0.24	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Three Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInThreeYears	0.23	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Fourth Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInFourthYears	0.08	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Fifth Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInFifthYears	0.04	pure
	neph	Stock Based Compensation Recognized Amortization Cost StockBasedCompensationRecognizedAmortizationCost	1008000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2496848	shares
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	1310000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2153000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6127000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32622377	shares
CY2015Q3	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	0	USD
CY2014Q3	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	-3428000	USD
	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	0	USD
	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	0	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-581000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-705000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2153000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6127000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8252777	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32622377	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33491189	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31366292	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23094457	shares
CY2015Q3	us-gaap	Inventory Gross InventoryGross	717000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	297000	USD
CY2015Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	52000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	111000	USD
CY2015Q3	neph	Annual Minimum Amount AnnualMinimumAmount	1000000	EUR
CY2015Q3	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	724000	USD
CY2015Q3	neph	Finite Lived Intangible Assets Amortization Expense Years Two And Three FiniteLivedIntangibleAssetsAmortizationExpenseYearsTwoAndThree	210000	USD
	neph	Royalty Rate RoyaltyRate	0.03	pure
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	NEPHROS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001196298
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	NEPH
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45025803	shares
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2099000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4007000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	86000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-125000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-104000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 - Organization and Nature of Operations</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in the hemodiafiltration, or HDF, modality to deliver therapy for ESRD patients. These are the OLpūr mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpūr H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter, which represented a new and complementary product line to the Company’s ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.  In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the valuation of the warrant liability, the collection of accounts receivable, value of inventories, useful lives of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.228	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0155	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45025803	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45025803	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30391513	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30391513	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	24000	USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	1610000	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3428000	USD
CY2015Q3	neph	Annual Minimum Amount AnnualMinimumAmount	1120000	USD
CY2015Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.12	pure
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	158000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-2099000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	9000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	65000	USD
	us-gaap	Interest Expense InterestExpense	30000	USD
	us-gaap	Interest Expense InterestExpense	277000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-581000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	2723000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-580000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2724000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2153000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6128000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	163000	USD
	neph	Issuance Of Shares For Future Services To Be Provided IssuanceOfSharesForFutureServicesToBeProvided	10000	USD
	neph	Issuance Of Shares For Future Services To Be Provided IssuanceOfSharesForFutureServicesToBeProvided	0	USD
CY2015Q3	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	53000	USD
CY2015Q3	neph	Royalty Receivable RoyaltyReceivable	29000	USD
	neph	Cash Received Fom Royalty CashReceivedFomRoyalty	29000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	58000	USD
CY2015Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	69231	shares
CY2015Q3	neph	Warrant Liability WarrantLiability	5287000	USD
CY2015Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	45000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	45000	USD
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	69231	shares
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	174000	USD
	neph	Stock Issued During Period Value Restricted Stock To Vendor StockIssuedDuringPeriodValueRestrictedStockToVendor	57000	USD
	neph	Commitment Fee CommitmentFee	135000	USD
	neph	Restricted Stock Issued To Settle Liability RestrictedStockIssuedToSettleLiability	174000	USD
	neph	Restricted Stock Issued To Settle Liability RestrictedStockIssuedToSettleLiability	0	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	158000	USD
CY2015Q3	neph	Restricted Stock Fair Value RestrictedStockFairValue	45000	USD
CY2015Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	389151	shares
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	13000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	47000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2015Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	USD
CY2015Q3	neph	Warrant Modification WarrantModification	1761000	USD
CY2014Q3	neph	Warrant Modification WarrantModification	0	USD
	neph	Warrant Modification WarrantModification	1761000	USD
	neph	Warrant Modification WarrantModification	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3000	USD
	neph	Stock Issued During Period Share Restricted Stock To Vendor StockIssuedDuringPeriodShareRestrictedStockToVendor	47382	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1390000	USD
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Stock Issued1 StockIssued1	27000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-064180-index-headers.html	Edgar Link	pending
0001144204-15-064180-index.html	Edgar Link	pending
0001144204-15-064180.txt	Edgar Link	pending
0001144204-15-064180-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
neph-20150930.xml	Edgar Link	completed
neph-20150930.xsd	Edgar Link	pending
neph-20150930_cal.xml	Edgar Link	unprocessable
neph-20150930_def.xml	Edgar Link	unprocessable
neph-20150930_lab.xml	Edgar Link	unprocessable
neph-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v421931_10q.htm	Edgar Link	pending
v421931_ex31-1.htm	Edgar Link	pending
v421931_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEPH
NEPHROS INC Stock $neph

2015 Q4 Form 10-Q Financial Statement

#000114420415064180 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH NEPHROS INC Stock $neph

2015 Q4 Form 10-Q Financial Statement

#000114420415064180 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH
NEPHROS INC Stock $neph